Human Leukocyte Antigens and Alloimmunization in Heart Transplantation: An Open Debate

Antonietta Picascia, Vincenzo Grimaldi, Amelia Casamassimi, Maria Rosaria De Pascale, Concetta Schiano, Claudio Napoli

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Considerable advances in heart transplantation outcome have been achieved through the improvement of donor-recipient selection, better organ preservation, lower rates of perioperative mortality and the use of innovative immunosuppressive protocols. Nevertheless, long-term survival is still influenced by late complications. We support the introduction of HLA matching as an additional criterion in the heart allocation. Indeed, allosensitization is an important factor affecting heart transplantation and the presence of anti-HLA antibodies causes an increased risk of antibody-mediated rejection and graft failure. On the other hand, the rate of heart-immunized patients awaiting transplantation is steadily increasing due to the limited availability of organs and an increased use of ventricular assist devices. Significant benefits may result from virtual crossmatch approach that prevents transplantation in the presence of unacceptable donor antigens. A combination of both virtual crossmatch and a tailored desensitization therapy could be a good compromise for a favorable outcome in highly sensitized patients. Here, we discuss the unresolved issue on the clinical immunology of heart transplantation.

Original languageEnglish
Pages (from-to)664-675
Number of pages12
JournalJournal of Cardiovascular Translational Research
Volume7
Issue number7
DOIs
Publication statusPublished - Oct 4 2014

Fingerprint

Heart Transplantation
HLA Antigens
Transplantation
Organ Preservation
Donor Selection
Heart-Assist Devices
Graft Rejection
Immunosuppressive Agents
Allergy and Immunology
Anti-Idiotypic Antibodies
Heart Rate
Antigens
Survival
Mortality
Antibodies
Therapeutics

Keywords

  • Anti-HLA antibodies
  • Antibody-mediated rejection
  • Cardiac allograft vasculopathy
  • Desensitization therapy
  • Heart transplantation
  • Solid-phase assays
  • Ventricular assist device

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Genetics
  • Genetics(clinical)
  • Molecular Medicine
  • Pharmaceutical Science
  • Medicine(all)

Cite this

Human Leukocyte Antigens and Alloimmunization in Heart Transplantation : An Open Debate. / Picascia, Antonietta; Grimaldi, Vincenzo; Casamassimi, Amelia; De Pascale, Maria Rosaria; Schiano, Concetta; Napoli, Claudio.

In: Journal of Cardiovascular Translational Research, Vol. 7, No. 7, 04.10.2014, p. 664-675.

Research output: Contribution to journalArticle

Picascia, Antonietta ; Grimaldi, Vincenzo ; Casamassimi, Amelia ; De Pascale, Maria Rosaria ; Schiano, Concetta ; Napoli, Claudio. / Human Leukocyte Antigens and Alloimmunization in Heart Transplantation : An Open Debate. In: Journal of Cardiovascular Translational Research. 2014 ; Vol. 7, No. 7. pp. 664-675.
@article{e1249d3b6bb745ea84ac140f3b3eba3a,
title = "Human Leukocyte Antigens and Alloimmunization in Heart Transplantation: An Open Debate",
abstract = "Considerable advances in heart transplantation outcome have been achieved through the improvement of donor-recipient selection, better organ preservation, lower rates of perioperative mortality and the use of innovative immunosuppressive protocols. Nevertheless, long-term survival is still influenced by late complications. We support the introduction of HLA matching as an additional criterion in the heart allocation. Indeed, allosensitization is an important factor affecting heart transplantation and the presence of anti-HLA antibodies causes an increased risk of antibody-mediated rejection and graft failure. On the other hand, the rate of heart-immunized patients awaiting transplantation is steadily increasing due to the limited availability of organs and an increased use of ventricular assist devices. Significant benefits may result from virtual crossmatch approach that prevents transplantation in the presence of unacceptable donor antigens. A combination of both virtual crossmatch and a tailored desensitization therapy could be a good compromise for a favorable outcome in highly sensitized patients. Here, we discuss the unresolved issue on the clinical immunology of heart transplantation.",
keywords = "Anti-HLA antibodies, Antibody-mediated rejection, Cardiac allograft vasculopathy, Desensitization therapy, Heart transplantation, Solid-phase assays, Ventricular assist device",
author = "Antonietta Picascia and Vincenzo Grimaldi and Amelia Casamassimi and {De Pascale}, {Maria Rosaria} and Concetta Schiano and Claudio Napoli",
year = "2014",
month = "10",
day = "4",
doi = "10.1007/s12265-014-9587-z",
language = "English",
volume = "7",
pages = "664--675",
journal = "Journal of Cardiovascular Translational Research",
issn = "1937-5387",
publisher = "Springer New York",
number = "7",

}

TY - JOUR

T1 - Human Leukocyte Antigens and Alloimmunization in Heart Transplantation

T2 - An Open Debate

AU - Picascia, Antonietta

AU - Grimaldi, Vincenzo

AU - Casamassimi, Amelia

AU - De Pascale, Maria Rosaria

AU - Schiano, Concetta

AU - Napoli, Claudio

PY - 2014/10/4

Y1 - 2014/10/4

N2 - Considerable advances in heart transplantation outcome have been achieved through the improvement of donor-recipient selection, better organ preservation, lower rates of perioperative mortality and the use of innovative immunosuppressive protocols. Nevertheless, long-term survival is still influenced by late complications. We support the introduction of HLA matching as an additional criterion in the heart allocation. Indeed, allosensitization is an important factor affecting heart transplantation and the presence of anti-HLA antibodies causes an increased risk of antibody-mediated rejection and graft failure. On the other hand, the rate of heart-immunized patients awaiting transplantation is steadily increasing due to the limited availability of organs and an increased use of ventricular assist devices. Significant benefits may result from virtual crossmatch approach that prevents transplantation in the presence of unacceptable donor antigens. A combination of both virtual crossmatch and a tailored desensitization therapy could be a good compromise for a favorable outcome in highly sensitized patients. Here, we discuss the unresolved issue on the clinical immunology of heart transplantation.

AB - Considerable advances in heart transplantation outcome have been achieved through the improvement of donor-recipient selection, better organ preservation, lower rates of perioperative mortality and the use of innovative immunosuppressive protocols. Nevertheless, long-term survival is still influenced by late complications. We support the introduction of HLA matching as an additional criterion in the heart allocation. Indeed, allosensitization is an important factor affecting heart transplantation and the presence of anti-HLA antibodies causes an increased risk of antibody-mediated rejection and graft failure. On the other hand, the rate of heart-immunized patients awaiting transplantation is steadily increasing due to the limited availability of organs and an increased use of ventricular assist devices. Significant benefits may result from virtual crossmatch approach that prevents transplantation in the presence of unacceptable donor antigens. A combination of both virtual crossmatch and a tailored desensitization therapy could be a good compromise for a favorable outcome in highly sensitized patients. Here, we discuss the unresolved issue on the clinical immunology of heart transplantation.

KW - Anti-HLA antibodies

KW - Antibody-mediated rejection

KW - Cardiac allograft vasculopathy

KW - Desensitization therapy

KW - Heart transplantation

KW - Solid-phase assays

KW - Ventricular assist device

UR - http://www.scopus.com/inward/record.url?scp=84919726908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919726908&partnerID=8YFLogxK

U2 - 10.1007/s12265-014-9587-z

DO - 10.1007/s12265-014-9587-z

M3 - Article

C2 - 25190542

AN - SCOPUS:84919726908

VL - 7

SP - 664

EP - 675

JO - Journal of Cardiovascular Translational Research

JF - Journal of Cardiovascular Translational Research

SN - 1937-5387

IS - 7

ER -